Immediate intraocular pressure changes following intravitreal injections of triamcinolone, pegaptanib, and bevacizumab.
OBJECTIVE
To assess the intraocular pressure (IOP) changes, within the first 30 min after intravitreal injection of 0.1 ml (4 mg) triamcinolone, 0.09 ml (0.3 mg) pegaptanib, and 0.05 ml (1.25 mg) bevacizumab.


METHODS
Records of patients who received intravitreal triamcinolone, pegaptanib, and bevacizumab and who had their IOP measured post-injection were reviewed.


RESULTS
A total of 212 injections were performed (76 bevacizumab in 63 patients, 42 triamcinolone in 41 patients, 94 pegaptanib in 74 patients). At 10 min, over 87% of eyes receiving each drug had an IOP of less than 35 mmHg. Three of the 42 eyes receiving intravitreal triamcinolone were treated with IOP-lowering drops for pressures of 44, 46, and 60 mmHg. No patients treated with intravitreal bevacizumab or pegaptanib received IOP-lowering drops. The number of eyes in each injection group that had an IOP rise >10 mmHg within 30 min after injection was 27.6% of eyes receiving bevacizumab, 33.3% of eyes receiving triamcinolone, and 36.2% of eyes receiving pegaptanib. At 10 min, eyes with glaucoma were less likely to have an IOP<35 mmHg, but this difference became less marked with time.


CONCLUSIONS
In our series, most patients receiving intravitreal injections did not require IOP-lowering drops after injection, and none required a paracentesis.
Bakri
S J
SJ
Department of Ophthalmology, Mayo Clinic, Rochester, MN 55905, USA. bakri.sophie@mayo.edu
Pulido
J S
JS
McCannel
C A
CA
Hodge
D O
DO
Diehl
N
N
Hillemeier
J
J
D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D052157:Aptamers, Nucleotide / Q000008:administration & dosage / Q000009:adverse effects*; D000068258:Bevacizumab; D006801:Humans; D015552:Injections, Intralesional; D007429:Intraocular Pressure / Q000187:drug effects; D009798:Ocular Hypertension / Q000139:chemically induced*; D009883:Ophthalmic Solutions / Q000008:administration & dosage / Q000009:adverse effects*; D019152:Paracentesis; D012075:Remission, Spontaneous; D012164:Retinal Diseases / Q000188:drug therapy*; D014221:Triamcinolone / Q000008:administration & dosage / Q000009:adverse effects*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D052157:Aptamers, Nucleotide; D009883:Ophthalmic Solutions; D014221:Triamcinolone; C495058:pegaptanib; D000068258:Bevacizumab